Literature DB >> 24902629

New inhaler devices - the good, the bad and the ugly.

Federico Lavorini1, Giovanni A Fontana, Omar S Usmani.   

Abstract

Drug delivery to the lungs is an effective way of targeting inhaled therapeutic aerosols and treating obstructive airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD). In the past 10 years, several new drugs for the management of asthma and COPD have been marketed and more are under development. These new therapeutic respiratory drugs have been furthered by innovations in all categories of pulmonary drug delivery systems to ensure optimal aerosolisation performance, consistency in efficacy and satisfactory patient adherence. In this review, we discuss the technological advances and innovations in recent inhaler devices and the evolving roles of pressurised metered-dose inhalers, dry powder inhalers and nebulisers, as well as their impact on patient adherence to treatment.
© 2014 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2014        PMID: 24902629     DOI: 10.1159/000363390

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  33 in total

1.  Real-world asthma management with inhaler devices in Switzerland-results of the asthma survey.

Authors:  Christian F Clarenbach; Laurent P Nicod; Malcolm Kohler
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 2.  The case for impulse oscillometry in the management of asthma in children and adults.

Authors:  Stanley P Galant; Hirsh D Komarow; Hye-Won Shin; Salman Siddiqui; Brian J Lipworth
Journal:  Ann Allergy Asthma Immunol       Date:  2017-06       Impact factor: 6.347

Review 3.  Optimising Inhaled Pharmacotherapy for Elderly Patients with Chronic Obstructive Pulmonary Disease: The Importance of Delivery Devices.

Authors:  Federico Lavorini; Claudia Mannini; Elisa Chellini; Giovanni A Fontana
Journal:  Drugs Aging       Date:  2016-07       Impact factor: 3.923

Review 4.  Asthma control: the right inhaler for the right patient.

Authors:  Nicola Scichilone
Journal:  Adv Ther       Date:  2015-04-07       Impact factor: 3.845

5.  Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues.

Authors:  Alessandro Roggeri; Claudio Micheletto; Daniela Paola Roggeri
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-03-21

6.  Identification of factors involved in medication compliance: incorrect inhaler technique of asthma treatment leads to poor compliance.

Authors:  Josep Darbà; Gabriela Ramírez; Antoni Sicras; Laura García-Bujalance; Saku Torvinen; Rainel Sánchez-de la Rosa
Journal:  Patient Prefer Adherence       Date:  2016-02-09       Impact factor: 2.711

7.  Expert Nordic perspectives on the potential of novel inhalers to overcome unmet needs in the management of obstructive lung disease.

Authors:  Anders Løkke; Lars Ahlbeck; Leif Bjermer; Jann Mortensen; Anders Østrem; Iris Pasternack; Guilherme Safioti; Saku Torvinen
Journal:  Eur Clin Respir J       Date:  2015-12-16

8.  The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients.

Authors:  Josep Darbà; Gabriela Ramírez; Antoni Sicras; Pablo Francoli; Saku Torvinen; Rainel Sánchez-de la Rosa
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-10-29

9.  Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data.

Authors:  Veronika Müller; Gabriella Gálffy; Márta Orosz; Zsuzsanna Kováts; Balázs Odler; Olof Selroos; Lilla Tamási
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-01-12

Review 10.  Patients' perspectives and preferences in the choice of inhalers: the case for Respimat(®) or HandiHaler(®).

Authors:  Pieter Nicolaas Richard Dekhuijzen; Federico Lavorini; Omar S Usmani
Journal:  Patient Prefer Adherence       Date:  2016-08-18       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.